A study of AK002 in patients with fibrotic disease.
Phase of Trial: Phase I
Latest Information Update: 12 Oct 2016
At a glance
- Drugs AK 002 (Primary)
- Indications Fibrosis
- Focus Adverse reactions; Therapeutic Use
- 12 Oct 2016 New trial record
- 26 Sep 2016 According to an Allakos media release, company plans to initiate this trial in the second half of 2017.